戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e of 8 or less who did not meet criteria for hypovolemic shock.
2 ew therapeutic approach for the treatment of hypovolemic shock.
3 eased vascular permeability that may lead to hypovolemic shock.
4 ension and acute renal failure, secondary to hypovolemic shock.
5 k syndrome is a very rare cause of recurrent hypovolemic shock.
6 (ED) because of recurrent abdominal pain and hypovolemic shock.
7 h in vivo model systems of histamine-induced hypovolemic shock.
8                                              Hypovolemic shock and hemorrhage continue to shape healt
9 ied Model for End-Stage Liver Disease score, hypovolemic shock, and bacterial infection at inclusion
10 ortality resulting from intestinal bleeding, hypovolemic shock, and sepsis, even at a very low DSS co
11 k: 3998 (31.5%), septic shock; 1457 (11.5%), hypovolemic shock; and 3625 (28.6%), other causes of sho
12 ude that L-NAME may blunt hypotension during hypovolemic shock by inhibiting nitric oxide synthase an
13                                              Hypovolemic shock causes a whole body ischemia/reperfusi
14 c activity and mean arterial pressure during hypovolemic shock compared with control rabbits.
15 olecular research applies more to protracted hypovolemic shock followed by the systemic inflammatory
16 cy, Model for End-Stage Liver Disease score, hypovolemic shock, hepatocellular carcinoma, and active
17                                              Hypovolemic shock, high-density lipoprotein, platelet co
18  randomized, double-blind trial of traumatic hypovolemic shock, HSD (250 mL) versus lactated Ringer's
19  induce plasma loss from the circulation and hypovolemic shock in animals.
20       IL-4 exacerbation of histamine-induced hypovolemic shock in mice was dependent on VE expression
21        Among patients with severe TBI not in hypovolemic shock, initial resuscitation with either hyp
22                           Hypotension during hypovolemic shock may be attributable, in part, to the f
23     The 30-day mortality rate was 18.4%, and hypovolemic shock (odds ratio 4.75; 95% confidence inter
24                                              Hypovolemic shock of marked severity and duration may pr
25 with shock or TBI occur within 24 hours from hypovolemic shock or TBI.
26 y to damage human cells in vitro and prevent hypovolemic shock, organ necrosis and death in mice with
27 during a prearrest control period and during hypovolemic shock produced by rapid hemorrhage of 35% of
28 d vs crystalloid solutions for management of hypovolemic shock remains unclear.
29 tcomes Consortium in patients with traumatic hypovolemic shock (shock) or traumatic brain injury (TBI
30  injured patients, age 15 years or more with hypovolemic shock [systolic blood pressure (SBP) </= 70
31                                       During hypovolemic shock there was a decrease in log low-freque
32 a variety of serious complications including hypovolemic shock, thrombocytopenia, and bleeding.
33  and left ventricular diameter compared with hypovolemic shock values by 34 +/- 2.5% and 20 +/- 2.5%,
34                                              Hypovolemic shock was maintained for 50 min.
35                                              Hypovolemic shock was present in 21.8% of patients, and
36 ons of hemorrhage, plasma extravasation, and hypovolemic shock, which leads to death.
37 ere largely protected from histamine-induced hypovolemic shock, which was associated with protection
38 l stratified by case mix (sepsis, trauma, or hypovolemic shock without sepsis or trauma).